The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Y ou’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence ...

U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its ...

Christine Allen, CEO and Co-Founder of Intrepid Labs, and Andy Lewis, CSO at Quotient Sciences, highlight their strategic ...

When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.

The adoption of AI in clinical trials holds the potential to revolutionize how therapies are discovered, but the pace of that ...

Eli Lilly is expanding its partnership with Insilico Medicine, an AI drug development company based in Hong Kong. Eli Lilly ...

Eli Lilly and Insilico Medicines' AI-centric collaboration further deepens relations between the two companies, which began in 2023.

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...

Insilico Medicine Cayman TopCo’s shares jumped on Monday after it struck an artificial intelligence-driven drug development ...

Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled ...

The convergence of two already fantastic industries is creating an incredible opportunity.